



Cancer Care Ontario

# Updates from the CCO Pathology & Laboratory Medicine Program

*OAP Annual General Meeting, Tremblant, Quebec*

SEPTEMBER 28TH, 2018

Aaron Pollett  
Provincial Head, Pathology and Laboratory Medicine Program  
Cancer Care Ontario

# Outline

- Regional Leads – Pathology and Laboratory
- AJCC 8<sup>th</sup> Edition and Electronic Cancer Checklists (eCC's)
- Biomarker Updates

# CCO Regional Leads – Pathology and Laboratory Medicine


LHIN	Representative	LHIN	Representative
1	Mohammad Alomari	8	Shaheda Handy
2	David Driman	9	Katie O'Reilly
3	Demo Divaris	10	Alexander Boag
4	Vina Alexopoulou	11	<i>TBC</i>
5 & 6	John Srigley	12	Russell Price
7N	David Hwang	13	Scott Kerrigan
7S	Ilan Weinreb	14	Meagan Kennedy

*Update: AJCC 8<sup>th</sup> Edition and Electronic  
Cancer Checklists*

# Update on transition to AJCC 8<sup>th</sup> Edition

- Implementation **deadline** for the synoptic electronic cancer checklists that are AJCC 8<sup>th</sup> edition compliant was **April 1, 2018**.
- Factors impacting the labs that are currently not reporting:
  - Vendor issues
  - Access to technical support
  - LIS issues
  - Budgetary constraints

*Laboratories reporting at or above minimum mandated version of CAP electronic cancer checklist (AJCC 8<sup>th</sup> edition) (September 2018)*



# *Biomarker Update*

# Current Complement of Tests



## CCO has oversight for:

- 9 tests covering 6 disease sites (breast, lung, colon, stomach, skin, gyne)
  - Test volume 2017/18 = 35,564
  - Test Funding = over \$6 million

Nov 2005  
Breast HER2

11/1/2005

Oct 2011  
Gastric HER2

Sep 2012  
BRAF

KRAS  
Jan 2013

Sep 2013  
ALK

EGFR  
Sep 2014

Apr 2018  
PD-L1

Oct 2018  
Lynch

BRCA (somatic)  
Aug 2018

New

12/31/2018

# Biomarker Update

## PD-L1

- Implemented April 1 2018
- Reflex testing on tumours from patients diagnosed with NSCLC (squamous and non-squamous/adenocarcinoma) regardless of stage
- Testing performed by Lung Testing Centres as part of comprehensive testing for NSCLC

## Somatic BRCA

- Implemented August 20, 2018
- Reflex testing on tumours from patients diagnosed with high grade serous ovarian, fallopian tube or primary peritoneal cancer, to determine drug eligibility for Olaparib
- Testing available at UHN and Sinai
- Additional sites can apply to perform testing in the near future

## Lynch Syndrome

- Reflex testing on patients under 70 years with CRC or endometrial cancer
- Target implementation date: October/November
- Testing Application deadlines:
  - September 14 2018
  - January 16 2019



# Current and Future Initiatives

- Developing best practice recommendations for the diagnosis of sarcoma
- Disease site testing:
  - Glioblastoma
  - Melanoma
  - Breast
- Minimal Residual Disease Testing in Acute Leukemia - guideline development with the CCO Program in Evidenced Based Care
- Synoptic reporting of biomarkers / genetics

Thank you

